Bendamustine Hydrochloride

"Bendamustine Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A nitrogen mustard compound that functions as an ALKYLATING ANTINEOPLASTIC AGENT and is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA and NON-HODGKIN'S LYMPHOMA.

Descriptor ID	D000069461
MeSH Number(s)	D02.241.081.114.625 D02.455.526.728.650.103 D03.633.100.103.123
Concept/Terms	Bendamustine Hydrochloride Bendamustine Hydrochloride Hydrochloride, Bendamustine Bendamustine Bendamustine Bendamustin Cytostasan Cytostasan IMET 3393 IMET 3393 Ribomustin Ribomustin Treanda Treanda Zimet 3393 Zimet 3393

Below are MeSH descriptors whose meaning is more general than "Bendamustine Hydrochloride".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Carboxylic Acids [D02.241]
Acids, Acyclic [D02.241.081]
Butyrates [D02.241.081.114]
Bendamustine Hydrochloride [D02.241.081.114.625]
Hydrocarbons [D02.455]
Hydrocarbons, Halogenated [D02.455.526]
Mustard Compounds [D02.455.526.728]
Nitrogen Mustard Compounds [D02.455.526.728.650]
Bendamustine Hydrochloride [D02.455.526.728.650.103]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Benzimidazoles [D03.633.100.103]
Bendamustine Hydrochloride [D03.633.100.103.123]

Below are MeSH descriptors whose meaning is more specific than "Bendamustine Hydrochloride".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Bendamustine Hydrochloride" by people in this website by year, and whether "Bendamustine Hydrochloride" was a major or minor topic of these publications.

Bar chart showing 8 publications over 6 distinct years, with a maximum of 2 publications in 2019 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2013	0	1	1
2014	0	1	1
2019	2	0	2
2020	0	2	2
2022	0	1	1
2024	1	0	1

Below are the most recent publications written about "Bendamustine Hydrochloride" by people in Profiles.

Logothetis CN, Horvat NP, Kurian T, Bello C, Chavez J, Isenalumhe L, Shah B, Sokol L, Saeed H, Pinilla J, Gaballa S. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience. Oncol Res. 2024; 32(6):1031-1036.

View in: PubMed
Alderuccio JP, Arcaini L, Watkins MP, Beaven AW, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert AB, Olszewski AJ, Kim SH, Hess B, Gaballa S, Ayyappan S, Castillo JJ, Argnani L, Voorhees TJ, Saba R, Chowdhury SM, Vargas F, Reis IM, Kwon D, Alexander JS, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link BK, Logothetis CN, Herrera AF, Friedberg JW, Kahl BS, Luminari S, Zinzani PL, Lossos IS. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022 04 12; 6(7):2035-2044.

View in: PubMed
Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, Le D? K, Arthur C, Pro B, Gritti G, Crump M, Petrich A, Samineni D, Sinha A, Punnoose EA, Szafer-Glusman E, Spielewoy N, Mobasher M, Humphrey K, Kornacker M, Hiddemann W. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood. 2020 12 03; 136(23):2628-2637.

View in: PubMed
Pan J, Ghimire S, Alpdogan SO, Chapman A, Carabasi M, DiMeglio M, Gong J, Martinez-Outschoorn U, Rose L, Ramirez M, Wagner JL, Weiss M, Flomenberg N, Pro B, Porcu P, Filicko-OHara J, Gaballa S. Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2021 03; 62(3):590-597.

View in: PubMed
Cohen JB, Wei L, Maddocks KJ, Christian B, Heffner LT, Langston AA, Lechowicz MJ, Porcu P, Flowers CR, Devine SM, Blum KA. Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. Cancer. 2020 03 15; 126(6):1235-1242.

View in: PubMed
Gomez-Arteaga A, Mark TM, Guarneri D, Christos PJ, Gergis U, Greenberg JD, Hsu J, Mayer SA, Niesvizky R, Pearse RN, Phillips AA, Rossi A, Coleman M, van Besien K, Shore TB. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2019 12; 54(12):2027-2038.

View in: PubMed
Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015 Jan 08; 125(2):242-8.

View in: PubMed
Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):831-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement